Bone marrow transplantation – how can we maximize cardiac status? Mini-review: highlights of cardio-oncology
Article Sidebar
Published:
Mar 3, 2016
Main Article Content
Abstract
None
Downloads
Download data is not yet available.
Metrics
Metrics Loading ...
Article Details
How to Cite
1.
Carver JR. Bone marrow transplantation – how can we maximize cardiac status?. OncoReview [Internet]. 2016Mar.3 [cited 2024Nov.23];6(1(21):8-10. Available from: https://journalsmededu.pl/index.php/OncoReview/article/view/469
Issue
Section
Articles
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
References
1. Jones LW, Haykowsky MJ, Swartz JJ et al. Early breast cancer therapy and cardiovascular injury. J Am Coll Cardiol 2007; 50(15): 1435-1441.
2. Lakoski SG, Eves ND, Douglas PS, Jones LW. Exercise rehabilitation in patients with cancer. Nat Rev Clin Oncol 2012; 9(5): 288-296.
3. Jones LW, Courneya KS, Mackey JR et al. Cardiopulmonary function and age-related decline across the breast cancer survivorship continuum. J Clin Oncol 2012; 30(20): 2530-2537.
4. Jones LW, Liu Q, Armstrong GT et al. Exercise and risk of major cardiovascular events in adult survivors of childhood Hodgkin lymphoma: a report from the childhood cancer survivor study. J Clin Oncol 2014; 32(32): 3643-3650.
5. Khouri MG, Hornsby WE, Risum N et al. Utility of 3-dimensional echocardiography, global longitudinal strain, and exercise stress echocardiography to detect cardiac dysfunction in breast cancer patients treated with doxorubicin-containing adjuvant therapy. Breast Cancer Res Treat 2014; 143(3): 531-539.
6. Khouri MG, Douglas PS, Mackey JR et al. Cancer therapy-induced cardiac toxicity in early breast cancer: addressing the unresolved issues. Circulation 2012; 126(23): 2749-2763.
7. CIBMTR – Center for International Blood and Marrow Transplant Research. Online: https://www.cibmtr.org/pages/index.aspx.
8. Nakamura R, Palmer JM, Chao J et al. Improved Outcome After Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplant (RI-HCT) For MDS Using Tacrolimus/Sirolimus As GVHD Prophylaxis. Biol Blood Marrow Transpl 2010; 16: S273-S274.
9. Passweg JR, Baldomero H, Bader P et al. European Society for Blood and Marrow Transplantation (EBMT). Hematopoietic SCT in Europe 2013: recent trends in the use of alternative donors showing more haploidenticaldonors but fewer cord blood transplants. Bone Marrow Transplant 2015; 50(4): 476-482.
10. Luznik L, Bolaños-Meade J, Zahurak M et al. High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease. Blood. 2010; 115(16): 3224-3230.
11. Ciurea SO, Zhang MJ, Bacigalupo AA et al. Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia. Blood 2015; 126(8): 1033-1040.
12. Fradley MG, Moslehi J. QT Prolongation and Oncology Drug Development. Card Electrophysiol Clin 2015; 7(2): 341-355.
13. Naing A, Veasey-Rodrigues H, Hong DS et al. Electrocardiograms (ECGs) in phase I anticancer drug development: the MD Anderson Cancer Center experience with 8518 ECGs. Ann Oncol 2012; 23(11): 2960-2963.
14. Miller WP, Shanley R, Dorostkar P. Cardiac QTc interval characteristics before and after hematopoietic stem cell transplantation: an analysis of 995 consecutive patients at a single center. Bone Marrow Transplant 2015; 50(7): 954-960.
15. O’Neal WT, Lakoski SG, Qureshi W et al. Relation between cancer and atrial fibrillation (from the Reasons for Geographic And Racial Differences in Stroke Study). Am J Cardiol 2015; 115(8):1090-1094.
16. Feliz V, Saiyad S, Ramarao SM et al. Melphalan-induced supraventricular tachycardia: incidence and risk factors. Clin Cardiol 2011; 34(6): 356-359.
17. Singla A, Hogan WJ, Ansell SM et al. Incidence of supraventricular arrhythmias during autologous peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 2013; 19(8): 1233-1237.
18. Tonorezos ES, Stillwell EE, Calloway JJ et al. Arrhythmias in the setting of hematopoietic cell transplants. Bone Marrow Transplant 2015; 50(9): 1212-1216.
2. Lakoski SG, Eves ND, Douglas PS, Jones LW. Exercise rehabilitation in patients with cancer. Nat Rev Clin Oncol 2012; 9(5): 288-296.
3. Jones LW, Courneya KS, Mackey JR et al. Cardiopulmonary function and age-related decline across the breast cancer survivorship continuum. J Clin Oncol 2012; 30(20): 2530-2537.
4. Jones LW, Liu Q, Armstrong GT et al. Exercise and risk of major cardiovascular events in adult survivors of childhood Hodgkin lymphoma: a report from the childhood cancer survivor study. J Clin Oncol 2014; 32(32): 3643-3650.
5. Khouri MG, Hornsby WE, Risum N et al. Utility of 3-dimensional echocardiography, global longitudinal strain, and exercise stress echocardiography to detect cardiac dysfunction in breast cancer patients treated with doxorubicin-containing adjuvant therapy. Breast Cancer Res Treat 2014; 143(3): 531-539.
6. Khouri MG, Douglas PS, Mackey JR et al. Cancer therapy-induced cardiac toxicity in early breast cancer: addressing the unresolved issues. Circulation 2012; 126(23): 2749-2763.
7. CIBMTR – Center for International Blood and Marrow Transplant Research. Online: https://www.cibmtr.org/pages/index.aspx.
8. Nakamura R, Palmer JM, Chao J et al. Improved Outcome After Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplant (RI-HCT) For MDS Using Tacrolimus/Sirolimus As GVHD Prophylaxis. Biol Blood Marrow Transpl 2010; 16: S273-S274.
9. Passweg JR, Baldomero H, Bader P et al. European Society for Blood and Marrow Transplantation (EBMT). Hematopoietic SCT in Europe 2013: recent trends in the use of alternative donors showing more haploidenticaldonors but fewer cord blood transplants. Bone Marrow Transplant 2015; 50(4): 476-482.
10. Luznik L, Bolaños-Meade J, Zahurak M et al. High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease. Blood. 2010; 115(16): 3224-3230.
11. Ciurea SO, Zhang MJ, Bacigalupo AA et al. Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia. Blood 2015; 126(8): 1033-1040.
12. Fradley MG, Moslehi J. QT Prolongation and Oncology Drug Development. Card Electrophysiol Clin 2015; 7(2): 341-355.
13. Naing A, Veasey-Rodrigues H, Hong DS et al. Electrocardiograms (ECGs) in phase I anticancer drug development: the MD Anderson Cancer Center experience with 8518 ECGs. Ann Oncol 2012; 23(11): 2960-2963.
14. Miller WP, Shanley R, Dorostkar P. Cardiac QTc interval characteristics before and after hematopoietic stem cell transplantation: an analysis of 995 consecutive patients at a single center. Bone Marrow Transplant 2015; 50(7): 954-960.
15. O’Neal WT, Lakoski SG, Qureshi W et al. Relation between cancer and atrial fibrillation (from the Reasons for Geographic And Racial Differences in Stroke Study). Am J Cardiol 2015; 115(8):1090-1094.
16. Feliz V, Saiyad S, Ramarao SM et al. Melphalan-induced supraventricular tachycardia: incidence and risk factors. Clin Cardiol 2011; 34(6): 356-359.
17. Singla A, Hogan WJ, Ansell SM et al. Incidence of supraventricular arrhythmias during autologous peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 2013; 19(8): 1233-1237.
18. Tonorezos ES, Stillwell EE, Calloway JJ et al. Arrhythmias in the setting of hematopoietic cell transplants. Bone Marrow Transplant 2015; 50(9): 1212-1216.